1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
4.150 USD   +11.56%
08/12Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT
08/11TRANSCRIPT : CorMedix Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : CorMedix Inc., Q1 2022 Earnings Call, May 12, 2022

05/12/2022 | 04:30pm EDT
Hello, and welcome to the CorMedix Inc. First Quarter 2022 Earnings Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call...


© S&P Capital IQ 2022
All news about CORMEDIX INC.
08/12Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT
08/11TRANSCRIPT : CorMedix Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/11CORMEDIX : Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Busine..
PU
08/11CORMEDIX : Q2 Earnings Snapshot
AQ
08/11Earnings Flash (CRMD) CORMEDIX Posts Q2 Revenue $21,253
MT
08/11CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides ..
AQ
08/11CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/09Top Midday Decliners
MT
08/09JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperfo..
MT
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -33,9 M - -
Net cash 2022 50,3 M - -
P/E ratio 2022 -4,86x
Yield 2022 -
Capitalization 171 M 171 M -
EV / Sales 2022 12 436x
EV / Sales 2023 109x
Nbr of Employees 30
Free-Float 98,8%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,15 $
Average target price 14,00 $
Spread / Average Target 237%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-8.79%171
MERCK KGAA-19.12%81 847
KYOWA KIRIN CO. LTD.1.59%12 813
SK BIOPHARMACEUTICALS CO., LTD.-18.52%4 754
BETTA PHARMACEUTICALS CO., LTD.-34.95%3 199
YUHAN CORPORATION-5.48%3 066